- Home
- XFOR vs ONCY Comparison
XFOR vs ONCY Comparison
Compare XFOR & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- ONCY
- Stock Information
- Founded
- XFOR 2014
- ONCY 1998
- Country
- XFOR United States
- ONCY Canada
- Employees
- XFOR N/A
- ONCY N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- ONCY Pharmaceuticals and Biotechnology
- Sector
- XFOR Health Care
- ONCY Health Care
- Exchange
- XFOR Nasdaq
- ONCY Nasdaq
- Market Cap
- XFOR 84.3M
- ONCY 89.7M
- IPO Year
- XFOR N/A
- ONCY 1999
- Fundamental
- Price
- XFOR $3.81
- ONCY $1.22
- Analyst Decision
- XFOR Strong Buy
- ONCY Strong Buy
- Analyst Count
- XFOR 3
- ONCY 5
- Target Price
- XFOR $34.17
- ONCY $5.00
- AVG Volume (30 Days)
- XFOR 1.4M
- ONCY 847.9K
- Earning Date
- XFOR 11-12-2025
- ONCY 11-11-2025
- Dividend Yield
- XFOR N/A
- ONCY N/A
- EPS Growth
- XFOR N/A
- ONCY N/A
- EPS
- XFOR N/A
- ONCY N/A
- Revenue
- XFOR $32,774,000.00
- ONCY N/A
- Revenue This Year
- XFOR $1,307.51
- ONCY N/A
- Revenue Next Year
- XFOR N/A
- ONCY N/A
- P/E Ratio
- XFOR N/A
- ONCY N/A
- Revenue Growth
- XFOR 5721.31
- ONCY N/A
- 52 Week Low
- XFOR $1.35
- ONCY $0.33
- 52 Week High
- XFOR $26.83
- ONCY $1.51
- Technical
- Relative Strength Index (RSI)
- XFOR 62.18
- ONCY 56.88
- Support Level
- XFOR $2.96
- ONCY $1.16
- Resistance Level
- XFOR $4.54
- ONCY $1.26
- Average True Range (ATR)
- XFOR 0.27
- ONCY 0.06
- MACD
- XFOR 0.07
- ONCY -0.00
- Stochastic Oscillator
- XFOR 55.75
- ONCY 95.12
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.